FDA approves Merck/Lilly combo for lung cancer; new PhRMA requirements result in expulsion of 22 members; Pfizer to pay Sangamo $7 million for gene therapy programs
PhRMA worked with WPP Health & Wellness and Young & Rubicam on creative for the ads.
Groups with PhRMA ties warn against drug-pricing proposals; patients learn how to be advocates; the U.K. will not cover Opdivo for head and neck cancer
Colorado's version of the FDA's compassionate use rule does not sit well with lobbying group Pharmaceutical Research and Manufacturers of America.
An analysis by Bloomberg today shows why drug pricing "keeps defying the law of gravity."
The group's offices will be in the DuBiotech research cluster.
Sanofi named in China corruption probe; GlaxoSmithKline starts a venture capital fund; and European non-profit AllTrials outlines its transparency goals
Companies are moving toward more access to clinical trial data. Despite their new stance, the internal battles haven't quite ended, some say.
China's industry investigation widens beyond GlaxoSmithKline; PhRMA's European equivalent rallies patient groups to fight transparency; Biogen Idec says a patient's death is not linked to Tecfidera; parents swap walk-in clinics for office visit; Roche continues its CEO hunt; and Forest logs 6% sales growth.
PhRMA talks up industry pipeline, Amgen's Aranesp fails to hit trial goals.
Congressional Republicans -- and even a few Democrats -- are pressing the attack on the Independent Payment Advisory Board for Medicare, a part of the Affordable Care Act opposed by both PhRMA and the AMA.
President Obama's proposed 2013 budget would mandate an estimated $156 billion in new rebates to low-income seniors through Medicare over the next decade - discounts that would come out of the pockets of drug companies and could cost tens of thousands of jobs, according to PhRMA.
A former Merck exec says it's time to wind down the DTC arms race by letting companies with brands in competitive categories collaborate on disease awareness advertising.
PhRMA named Business Roundtable chief John Castellani as its president and CEO, tapping a longtime trade association hand to replace former Congressional kingpin Billy Tauzin.
PhRMA said the reasoning behind a sharp cap on samples mandated by its European counterpart doesn't apply in the US.
Billy Tauzin is stepping down as head of PhRMA amid speculation that the derailment of healthcare reform has empowered an anti-reform faction within the group. Tauzin, who has moved the group toward the Democrats and negotiated with the White House over the legislation, will leave PhRMA at the end of June.
The top Republican in the House of Representatives accused PhRMA of "appeasing" the Obama administration, which he cast as a bully who "asks for your lunch money." PhRMA responded that its pro-reform campaign is "absolutely consistent with our core principles."
The first execution in PhRMA's promised pro-health reform campaign -- a $12 million TV spot aimed at communicating how the legislation will impact individuals -- airs today
PhRMA has committed to finding $80 billion in savings on drugs sold in the US over 10 years, including selling drugs at half-price to seniors in the Medicare Part D "donut hole" coverage gap.